CN111344009A - 人巨细胞病毒免疫原性组合物 - Google Patents

人巨细胞病毒免疫原性组合物 Download PDF

Info

Publication number
CN111344009A
CN111344009A CN201880072392.9A CN201880072392A CN111344009A CN 111344009 A CN111344009 A CN 111344009A CN 201880072392 A CN201880072392 A CN 201880072392A CN 111344009 A CN111344009 A CN 111344009A
Authority
CN
China
Prior art keywords
hcmv
leu
immunogenic composition
antigen
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880072392.9A
Other languages
English (en)
Chinese (zh)
Inventor
P·乔克斯
R·杜马斯
J·海恩斯勒
S·皮雄
F·皮拉斯-杜斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN111344009A publication Critical patent/CN111344009A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880072392.9A 2017-09-13 2018-09-11 人巨细胞病毒免疫原性组合物 Pending CN111344009A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17306179.7 2017-09-13
EP17306179 2017-09-13
PCT/EP2018/074369 WO2019052975A1 (en) 2017-09-13 2018-09-11 IMMUNOGENIC COMPOSITION AGAINST HUMAN CYTOMEGALOVIRUS

Publications (1)

Publication Number Publication Date
CN111344009A true CN111344009A (zh) 2020-06-26

Family

ID=60782111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880072392.9A Pending CN111344009A (zh) 2017-09-13 2018-09-11 人巨细胞病毒免疫原性组合物

Country Status (12)

Country Link
US (4) US11524069B2 (https=)
EP (1) EP3681534A1 (https=)
JP (2) JP7770767B2 (https=)
KR (2) KR20200051778A (https=)
CN (1) CN111344009A (https=)
AU (1) AU2018331874B2 (https=)
BR (1) BR112020004747A2 (https=)
IL (1) IL273120B2 (https=)
MX (1) MX2020002810A (https=)
SG (1) SG11202002174SA (https=)
WO (1) WO2019052975A1 (https=)
ZA (1) ZA202001561B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
CA3121915C (en) * 2018-12-10 2025-05-20 Km Biologics Co., Ltd. VACCINE FOR THE PREVENTION OR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTION
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
AU2021367917A1 (en) * 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2024218752A1 (en) * 2023-04-21 2024-10-24 Instar Technologies A.S. Pharmaceutical composition for vaccination against cytomegalovirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242152A1 (en) * 2011-07-06 2014-08-28 Andrew Geall Immunogenic compositions and uses thereof
CN104853771A (zh) * 2012-07-06 2015-08-19 诺华股份有限公司 巨细胞病毒蛋白的复合物
WO2017070613A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5547834A (en) 1988-01-29 1996-08-20 Chiron Corporation Recombinant CMV neutralizing proteins
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0388186A1 (en) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company External regulation of gene expression
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US20020102562A1 (en) 1995-05-24 2002-08-01 Pasteur Merieux Serums Et Vaccines S.A. Recombinant CMV neutralizing proteins
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
EP2263687B1 (en) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP3031469B1 (en) * 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
WO2009037359A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infections
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EP2627352B1 (en) 2010-10-15 2017-05-10 GlaxoSmithKline Biologicals S.A. Cytomegalovirus gb antigen
EA027236B1 (ru) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CN110241137A (zh) 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
CA2885145A1 (en) * 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
WO2017044895A2 (en) * 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
BR112018076015A8 (pt) * 2016-06-17 2022-06-28 Sanofi Pasteur Formulações imunogênicas compreendendo adjuvantes de polímero do ácido poliacrílico linear ou ramificado .
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140242152A1 (en) * 2011-07-06 2014-08-28 Andrew Geall Immunogenic compositions and uses thereof
CN104853771A (zh) * 2012-07-06 2015-08-19 诺华股份有限公司 巨细胞病毒蛋白的复合物
WO2017070613A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILGERS LAT等: "Alkyl-esters of polyacrylic acid as vaccine adjuvants", VACCINE, vol. 16, no. 16, 31 October 1998 (1998-10-31), pages 1575 - 1581, XP004129211, DOI: 10.1016/S0264-410X(98)00047-4 *
MARK R S等: "Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protectfemale guinea pigs against cytomegalovirus (CMV) viremia andoffspring mortality in a CMV-challenge model", VACCINE, vol. 32, 16 July 2013 (2013-07-16), pages 2756 - 2762 *

Also Published As

Publication number Publication date
MX2020002810A (es) 2020-07-21
RU2020113253A (ru) 2021-10-18
KR20200051778A (ko) 2020-05-13
AU2018331874A1 (en) 2020-04-30
RU2020113253A3 (https=) 2021-11-17
JP2024026160A (ja) 2024-02-28
JP2020533354A (ja) 2020-11-19
US20250228933A1 (en) 2025-07-17
BR112020004747A2 (pt) 2020-09-24
EP3681534A1 (en) 2020-07-22
IL273120B1 (en) 2023-06-01
JP7770767B2 (ja) 2025-11-17
WO2019052975A1 (en) 2019-03-21
ZA202001561B (en) 2021-07-28
US20200276301A1 (en) 2020-09-03
NZ763438A (en) 2025-03-28
SG11202002174SA (en) 2020-04-29
WO2019052975A9 (en) 2020-04-09
KR20250006307A (ko) 2025-01-10
CA3075207A1 (en) 2019-03-21
US20210023202A1 (en) 2021-01-28
IL273120A (en) 2020-04-30
US11207403B2 (en) 2021-12-28
US11524069B2 (en) 2022-12-13
US20230277655A1 (en) 2023-09-07
AU2018331874B2 (en) 2022-06-02
IL273120B2 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
US12421283B2 (en) Compositions and methods for treatment of cytomegalovirus
US11207403B2 (en) Human cytomegalovirus immunogenic composition
John et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity
CA2600905A1 (en) Vaccine
CN116847830A (zh) 含tlr4激动剂的脂质体、其制备和用途
EP2714076A1 (en) Inactivated dengue virus vaccine
WO2019055887A1 (en) PSEUDO-VIRAL PARTICLES OF MULTIVALENT EPSTEIN-BARR VIRUS AND USES THEREOF
CA3142132A1 (en) Vaccine compositions for the treatment of coronavirus
CN116217736A (zh) 用于避免感染与治疗远程新冠肺炎之针对SARS-CoV-2变体的疫苗组成物
CA3075207C (en) Human cytomegalovirus immunogenic composition
RU2775424C2 (ru) Иммуногенная композиция цитомегаловируса человека
WO2022046634A1 (en) Vaccines against sars-cov-2 infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: France

Address after: lyon

Applicant after: Sanofi Vaccine Research and Development Co.

Address before: lyon

Applicant before: SANOFI PASTEUR

Country or region before: France